Search Result

Results for "

Nonalcoholic steatohepatitis (NASH)

" in MedChemExpress (MCE) Product Catalog:

By Targets:	17β-HSD (19) Acetyl-CoA Carboxylase (3) Acyltransferase (1) Amino acid Transporter (1) Aminotransferases (Transaminases) (1) AMPK (2) Apical Sodium-Dependent Bile Acid Transporter (1) Apoptosis (1) ASK1 (1) Autophagy (4) Bacterial (1) Biochemical Assay Reagents (1) Caspase (1) CCR (1) ClpP (1) Cyclophilin (1) Cytochrome P450 (3) Dipeptidyl Peptidase (1) Drug Isomer (1) Drug Metabolite (2) Endogenous Metabolite (5) Eukaryotic Initiation Factor (eIF) (1) FXR (12) GCGR (5) GLP Receptor (11) GPR119 (2) HCV (2) HIV (1) HSP (1) Insulin Receptor (1) Interleukin Related (3) Isotope-Labeled Compounds (3) JNK (1) Ketohexokinase (2) LDLR (1) Lipoxygenase (1) Mitochondrial Metabolism (4) Neurokinin Receptor (1) NF-κB (4) Nuclear Factor of activated T Cells (NFAT) (1) OAT (1) p38 MAPK (1) Phosphatase (1) PPAR (5) RAR/RXR (2) Reactive Oxygen Species (ROS) (1) Reference Standards (3) Sirtuin (1) SphK (2) STAT (2) Stearoyl-CoA Desaturase (SCD) (1) TAM Receptor (1) TGF-beta/Smad (2) Thyroid Hormone Receptor (6) TNF Receptor (2)
By Research Areas:	Cancer (8) Cardiovascular Disease (3) Infection (3) Inflammation/Immunology (41) Metabolic Disease (59) Neurological Disease (3)

By Targets:

17β-HSD (19)

Acetyl-CoA Carboxylase (3)

Acyltransferase (1)

Amino acid Transporter (1)

Aminotransferases (Transaminases) (1)

AMPK (2)

Apical Sodium-Dependent Bile Acid Transporter (1)

Apoptosis (1)

ASK1 (1)

Autophagy (4)

Bacterial (1)

Biochemical Assay Reagents (1)

Caspase (1)

CCR (1)

ClpP (1)

Cyclophilin (1)

Cytochrome P450 (3)

Dipeptidyl Peptidase (1)

Drug Isomer (1)

Drug Metabolite (2)

Endogenous Metabolite (5)

Eukaryotic Initiation Factor (eIF) (1)

FXR (12)

GCGR (5)

GLP Receptor (11)

GPR119 (2)

HCV (2)

HIV (1)

HSP (1)

Insulin Receptor (1)

Interleukin Related (3)

Isotope-Labeled Compounds (3)

JNK (1)

Ketohexokinase (2)

LDLR (1)

Lipoxygenase (1)

Mitochondrial Metabolism (4)

Neurokinin Receptor (1)

NF-κB (4)

Nuclear Factor of activated T Cells (NFAT) (1)

OAT (1)

p38 MAPK (1)

Phosphatase (1)

PPAR (5)

RAR/RXR (2)

Reactive Oxygen Species (ROS) (1)

Reference Standards (3)

Sirtuin (1)

SphK (2)

STAT (2)

Stearoyl-CoA Desaturase (SCD) (1)

TAM Receptor (1)

TGF-beta/Smad (2)

Thyroid Hormone Receptor (6)

TNF Receptor (2)

By Research Areas:

Cancer (8)

Cardiovascular Disease (3)

Infection (3)

Inflammation/Immunology (41)

Metabolic Disease (59)

Neurological Disease (3)

Inhibitors & Agonists

Bibliotecas de Screening

Peptides

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Glycolithocholic acid 2 Publications Verification Lithocholylglycine	Endogenous Metabolite	Inflammation/Immunology
Glycolithocholic acid (Lithocholylglycine), an endogenous metabolite, is a glycine-conjugated secondary bile acid. Glycolithocholic acid can be used to diagnose ulcerative colitis (UC), non-alcoholic steatohepatitis (NASH) and primary sclerosing cholangitis (PSC) .

Cilofexor Maximum Cited Publications 10 Publications Verification GS-9674	FXR Autophagy	Inflammation/Immunology
Cilofexor (GS-9674) is a potent, selective and orally active nonsteroidal FXR agonist with an EC₅₀ of 43 nM. Cilofexor has anti-inflammatory and antifibrotic effects. Cilofexor has the potential for primary sclerosing cholangitis (PSC) and nonalcoholic steatohepatitis (NASH) research .

Beinaglutide 1 Publications Verification GLP-1 (human)	GCGR	Metabolic Disease Inflammation/Immunology
Beinaglutide is a human GLP-1 polypeptide that shares almost 100% homology with human GLP-1 (7–36). Beinaglutide displays does-dependent effects in glycemic control, inhibiting food intake and gastric empty and promoting weight loss. Beinaglutide has the potential for the research of overweight/obesity and nonalcoholic steatohepatitis (NASH) .

Pemvidutide ALT-801	GLP Receptor GCGR	Metabolic Disease
Pemvidutide (ALT-801) is a GLP-1R/GCGR dual agonist, shows striking reductions in body weight, liver fat and serum lipids. Pemvidutide can be used in non-alcoholic steatohepatitis (NASH) and obesity research .

Icomidocholic acid 1 Publications Verification Aramchol; C20-FABAC	Stearoyl-CoA Desaturase (SCD)	Metabolic Disease
Icomidocholic acid (Aramchol) is a lipid molecule synthesized from cholic acid and arachidic acid. Icomidocholic acid is an orally active SCD1 inhibitor and cholesterol solubilizer with antifibrotic effects. Icomidocholic acid can reduce liver fat content, dissolve cholesterol crystals and prevent gallstone formation. Icomidocholic acid can be used in the study of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) .

Berberine ursodeoxycholate 1 Publications Verification HTD1801; BUDCA	Biochemical Assay Reagents	Metabolic Disease
Berberine ursodeoxycholate (HTD1801), an ionic salt of Berberine and Ursodeoxycholic acid, is an orally active and potent hypolipidemic agent. Berberine ursodeoxycholate shows significantly great reduction in liver fat content. Berberine ursodeoxycholate has a broad spectrum of metabolic activity. Berberine ursodeoxycholate can be used for the research of hyperlipidemia, non-alcoholic steatohepatitis (NASH) and diabetes .

BI-3231 2 Publications Verification	17β-HSD	Metabolic Disease
BI 3231, a chemical probe, is a potent and selective hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) inhibitor, with IC₅₀s of 1 and 13 nM for hHSD17B13 and mHSD17B13, respectively. BI 3231 has the potential for the research of nonalcoholic steatohepatitis (NASH) and other liver diseases .

2-Oleoylglycerol 1 Publications Verification 2-OG	GPR119 NF-κB TGF-beta/Smad GLP Receptor	Metabolic Disease
2-Oleoylglycerol (2-OG) is a lipid found in the diet. It is a GPR119 agonist, with an EC₅₀ value of 2.5 μM in activating hGPR119 in transiently transfected COS-7 cells. 2-Oleoylglycerol enhances the inflammatory response of macrophages and promotes fibrosis by activating the GPR119/TAK1/NF-κB/TGF-β1 signaling pathway. It also stimulates glucagon-like peptide 1 (GLP-1) secretion in vivo. 2-Oleoylglycerol is expected to be used in the research of non-alcoholic steatohepatitis (NASH) .

(4S)-GLP-1 receptor agonist 14	GLP Receptor	Metabolic Disease Inflammation/Immunology
(4S)-GLP-1 receptor agonist 14 is a potent and orally active GLP-1 receptor agonist with an EC₅₀ ≤ 20 nM. (4S)-GLP-1 receptor agonist 14 can be used for research on diabetes, obesity, metabolic diseases, cardiovascular diseases, liver diseases, nonalcoholic steatohepatitis (NASH), and other diseases associated with GLP-1 receptor .

RU-301 1 Publications Verification	TAM Receptor	Inflammation/Immunology Cancer
RU-301 is a pan TAM inhibitor that blocks Gas6-induced TAM activation and tumorigenicity. RU-301 significantly reduces nonalcoholic steatohepatitis (NASH) fibrosis, along with attenuates ERK activation and TGFβ1 expression. RU-301 can be used in studies of cancer and nonalcoholic steatohepatitis .

Azemiglitazone 1 Publications Verification MSDC-0602	Mitochondrial Metabolism PPAR	Neurological Disease Metabolic Disease Inflammation/Immunology
Azemiglitazone (MSDC-0602) is an orally active thiazolidinedione (TZD) -like molecule, which binds to PPARγ with low binding and activating affinity. Azemiglitazone inhibits mitochondrial pyruvate carrier (MPC), which inhibits Alzheimer’s disease and diminishes nonalcoholic steatohepatitis (NASH) caused liver injury .

Leronlimab PRO 140	CCR HIV	Infection Cancer
Leronlimab (PRO 140) is a humanized IgG4 anti-CCR5 monoclonal antibody. Leronlimab inhibits CCR5-mediated HIV-1 viral and lung metastasis in mouse tumor models. Leronlimab can be used for the research of HIV nonalcoholic steatohepatitis (NASH) and cancer .

Peretinoin 5+ Cited Publications NIK333	RAR/RXR SphK Autophagy HCV	Infection Cancer
Peretinoin is an oral acyclic retinoid with a vitamin A-like structure that targets retinoid nuclear receptors such as retinoid X receptor (RXR) and retinoic acid receptor (RAR). Peretinoin reduces the mRNA level of sphingosine kinase 1 (SPHK1) in vitro by downregulating a transcription factor, Sp1 . Peretinoin prevents the progression of non-alcoholic steatohepatitis (NASH) and the development of hepatocellular carcinoma (HCC) through activating the autophagy pathway by increased Atg16L1 expression . Peretinoin inhibits HCV RNA amplification and virus release by altering lipid metabolism with a EC₅₀ of 9 μM .

TBPH	Mitochondrial Metabolism Cytochrome P450 TNF Receptor Interleukin Related HSP LDLR Eukaryotic Initiation Factor (eIF) ClpP	Metabolic Disease Inflammation/Immunology
TBPH is a brominated flame retardant. TBPH enhances hepatic steatosis, inflammation, and fibrosis in mice with nonalcoholic steatohepatitis (NASH). TBPH induces dysregulation of phospholipid metabolism, reducing cardiolipin (CL) and phosphatidylserine (PS) levels. TBPH leads to impaired endoplasmic reticulum-mitochondria (ER-Mito) contacts, subsequently causing mitochondrial dysfunction. TBPH induces lung injury through an inflammatory response mediated by mitochondria-derived ds-DNA. TBPH can be used to study the role of MFN2-mediated ER-mitochondria contacts in lipid metabolism homeostasis .

Anti-Mouse NK1.1 Antibody (PK136)	Neurokinin Receptor NF-κB STAT	Inflammation/Immunology
Anti-Mouse NK1.1 Antibody (PK136) is an anti-mouse NK1.1 IgG2a monoclonal antibody. Anti-Mouse NK1.1 Antibody (PK136) can deplete natural killer (NK) cells. Anti-Mouse NK1.1 Antibody (PK136) inhibits the JAK-STAT and NF-κB signaling pathways. Anti-Mouse NK1.1 Antibody (PK136) can be used for research on inflammation conditions such as non-alcoholic steatohepatitis (NASH) .

PXL770	AMPK	Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
PXL770 is an orally active, direct allosteric AMP-activated protein kinase (AMPK) activator. PXL770 decreases C26:0 levels, improves mitochondrial respiration, reduces expression of proinflammatory genes and induces expression of compensatory transporters (ABCD2/3) in ALD fibroblasts/lymphocytes. PXL770 normalizes plasma VLCFA levels, significantly reduces elevated VLCFA levels in brain and spinal cord in Abcd1 KO mice. PXL770 improves glycemia, dyslipidemia, and insulin resistance in ob/ob and high-fat diet (HFD)-fed mice. PXL770 can be used for the study of X-linked adrenoleukodystrophy (ALD), autosomal dominant polycystic kidney disease and nonalcoholic steatohepatitis (NASH) .

Volixibat SHP626; LUM002	Apical Sodium-Dependent Bile Acid Transporter	Metabolic Disease
Volixibat (SHP626) is a highly selective, minimally absorbed, and competitive apical sodium-dependent bile acid transporter (ASBT) inhibitor. Volixibat has potential for treatment for non-alcoholic steatohepatitis (NASH) .

THR-β agonist 2	Thyroid Hormone Receptor	Metabolic Disease
THR-β agonist 2 is a potent agonist of THR-β. THR-β agonist 2 has the potential for the research of metabolic diseases such as obesity, hyperlipidemia, hypercholesterolemia, diabetes and other conditions such as steatosis and non-alcoholic steatohepatitis (NASH), atherosclerosis and other related conditions and diseases (extracted from patent WO2021121210A1, compound 3) .

Rencofilstat 1 Publications Verification CRV431	Cyclophilin Sirtuin Nuclear Factor of activated T Cells (NFAT) Interleukin Related	Cancer
Rencofilstat (CRV431) is an orally active pan-cyclophilin inhibitor with IC₅₀ values of 2.5 nM, 3.1 nM, 2.8 nM, 7.3 nM for Cyp A, CypB, Cyp D and Cyp G, respectively. Rencofilstat reduces fibrosis and tumor growth in models of chronic liver disease. Rencofilstat can be used for the study of nonalcoholic steatohepatitis (NASH), hepatocellular carcinoma and viral hepatitis-induced liver disease .

Nidufexor LMB763	FXR Autophagy	Inflammation/Immunology
Nidufexor (LMB763) is an orally-available farnesoid X receptor (FXR) agonist for the research of nonalcoholic steatohepatitis (NASH) .

Omesdafexor MET409	FXR	Inflammation/Immunology Cancer
Omesdafexor (MET409) is an orally active FXR agonist with a unique non-bile acid structure. Omesdafexor can be used for the study of non-alcoholic steatohepatitis (NASH) .

EDP-305	FXR Phosphatase Cytochrome P450	Inflammation/Immunology
EDP-305 is an orally active, potent and selective farnesoid X receptor (FXR) agonist, with EC₅₀ values of 34 nM (chimeric FXR in CHO cells) and 8 nM (full-length FXR in HEK cells). EDP-305 shows a potent and consistent antifibrotic effect. EDP-305 can be used for primary biliary cholangitis (PBC) and non-alcoholic steatohepatitis (NASH) research .

Glycolithocholic acid sodium 2 Publications Verification Lithocholylglycine sodium	Endogenous Metabolite	Metabolic Disease
Glycolithocholic acid (Lithocholylglycine) sodium is the sodium salt of Glycolithocholic acid. Glycolithocholic acid is a glycine-conjugated secondary bile acid. Glycolithocholic acid can be used to diagnose ulcerative colitis (UC), non-alcoholic steatohepatitis (NASH) and primary sclerosing cholangitis (PSC) .

GIP/GLP-1 dual receptor agonist-1 sodium	GLP Receptor GCGR	Inflammation/Immunology
GIP/GLP-1 dual receptor agonist-1 sodium is a GIP/GLP-1 dual receptor agonist. GIP/GLP-1 dual receptor agonist-1 sodium is used in the research of metabolic disorders and fatty liver diseases, including non-alcoholic steatohepatitis (NASH) and non-alcoholic fatty liver disease (NAFLD) .

GIP/GLP-1 dual receptor agonist-1	GCGR GLP Receptor	Inflammation/Immunology
GIP/GLP-1 dual receptor agonist-1 is a GIP/GLP-1 dual receptor agonist. GIP/GLP-1 dual receptor agonist-1 is used in the research of metabolic disorders and fatty liver diseases, including non-alcoholic steatohepatitis (NASH) and non-alcoholic fatty liver disease (NAFLD) .

FXR antagonist 1	FXR	Metabolic Disease
FXR antagonist 1 (compound F6) is an orally active and selective intestinal FXR antagonist (IC₅₀=2.1 μM). FXR antagonist 1 selectively inhibits intestinal FXR signalling through antagonism of intestinal FXR and feedback activation of hepatic FXR to improve hepatic steatosis, inflammation and fibrosis in NASH (nonalcoholic steatohepatitis) models. FXR antagonist 1 can be used in NASH studies .

11,12-DiHETrE	Drug Metabolite	Inflammation/Immunology
11,12-DiHETrE is a dihydroxy fatty acid metabolite of Arachidonic Acid (HY-109590). 11,12-DiHETrE is converted to 11,12-DiHETrE under elevated soluble epoxide hydrolase (sEH) activity, a process closely related to inflammation and oxidative stress. 11,12-DiHETrE can serve as a single biomarker to differentiate between NAFL (non-alcoholic fatty liver disease) and NASH (non-alcoholic steatohepatitis). 11,12-DiHETrE can be used in studies on preterm birth, autism, and pulmonary hypertension .

LY3522348 KHK-IN-3	Ketohexokinase	Cardiovascular Disease Metabolic Disease Inflammation/Immunology
KHK-IN-3 (Example 1) is a ketohexokinase (KHK) inhibitor. KHK-IN-3 can be used in the study of kidney disease, nonalcoholic steatohepatitis (NASH), diabetes and heart failure. KHK is a rate-limiting enzyme and fructokinase involved in fructose metabolism. KHK catalyzes the phosphorylation of fructose to fructose-1-phosphate (FIP) at the expense of ATP. The lack of feedback inhibition of fructose metabolism triggers the accumulation of downstream intermediates such as lipogenesis, gluconeogenesis, and oxidative phosphorylation .

Pemvidutide TFA ALT-801 TFA	GLP Receptor GCGR	Metabolic Disease
Pemvidutide (ALT-801) TFA is a GLP-1R/GCGR dual agonist, shows striking reductions in body weight, liver fat and serum lipids. Pemvidutide TFA can be used in non-alcoholic steatohepatitis (NASH) and obesity research .

TRβ agonist 1	Thyroid Hormone Receptor	Metabolic Disease
TRβ agonist 1 is a selective and mutation-sensitive thyroid hormone receptor β (TRβ) agonist, with an EC₅₀ value of 21 nM. TRβ agonist 1 can be used for researching dyslipidemia, nonalcoholic steatohepatitis (NASH), and resistance to thyroid hormone (RTH) .

HPG1860	FXR Aminotransferases (Transaminases)	Metabolic Disease Inflammation/Immunology
HPG1860 is an orally active, highly selective and potent FXR agonist, with an EC₅₀ of 18 nM (FXR-luciferase reporter assay). HPG1860 has EC₅₀ values >30.0 μM for TGR5 and 13 other related nuclear receptors (cAMP biological assay). HPG1860 can be used for the research of non-alcoholic steatohepatitis (NASH) .

ZLY28	FXR	Metabolic Disease
ZLY28 is the first-in-class intestinal restricted and orally active FXR and FABP1 dual modulator. ZLY28 also is a novel anti-NASH agent. ZLY28 can be used for the research of nonalcoholic steatohepatitis (NASH) .

V023-9340	FXR	Metabolic Disease
V023-9340 is a potent FXR inhibitor with IC₅₀ of 4.27 μM that can be used in NASH (nonalcoholic steatohepatitis) research .

Seladelpar (lysine dihydrate) 1 Publications Verification MBX-8025 (lysine dihydrate); RWJ-800025 (lysine dihydrate)	PPAR Interleukin Related	Cardiovascular Disease Metabolic Disease Inflammation/Immunology
Seladelpar Lysine dihydrate (MBX-8025 lysine dihydrate) is an orally active, selective PPAR-δ agonist with an EC₅₀ of 2 nM against hPPAR-δ. Seladelpar Lysine dihydrate reduces serum IL-31 and bile acid levels. It alleviates pruritus symptoms. Seladelpar Lysine dihydrate enhances insulin sensitivity, normalizes levels of hyperglycemia, hyperinsulinemia, glucose disposal capacity, serum lipids and hepatic free cholesterol. It reduces steatosis, hepatic inflammation and improves liver fibrosis. Seladelpar Lysine dihydrate reverses the pathological changes of non-alcoholic steatohepatitis (NASH). It is applicable to research related to primary biliary cholangitis and non-alcoholic steatohepatitis (NASH) .

SLC6A19-IN-2	Amino acid Transporter	Metabolic Disease
SLC6A19-IN-2 (Example 4) is a potent SLC6A19 inhibitor with an IC₅₀ of 14 nM. SLC6A19-IN-2 can be used for the study of metabolic diseases such as nonalcoholic steatohepatitis (NASH), nonalcoholic fatty liver disease (NAFLD) and phenylketonuria (PKU) .

IMA-1	Lipoxygenase Acetyl-CoA Carboxylase	Metabolic Disease
IMA-1 is an inhibitor that inhibits the interaction between arachidonic acid 12-lipoxygenase (ALOX12) and acetyl-CoA carboxylase 1 (ACC1). IMA-1 significantly blocks the progression of diet-induced non-alcoholic steatohepatitis (NASH) in male mice and crab-eating monkeys, and does not cause hyperlipidemia. IMA-1 can be used for the study of NASH .

Glycolithocholic acid (Standard) Lithocholylglycine (Standard)	Endogenous Metabolite Reference Standards	Inflammation/Immunology
Glycolithocholic acid (Standard) is the analytical standard of Glycolithocholic acid. This product is intended for research and analytical applications. Glycolithocholic acid (Lithocholylglycine), an endogenous metabolite, is a glycine-conjugated secondary bile acid. Glycolithocholic acid can be used to diagnose ulcerative colitis (UC), non-alcoholic steatohepatitis (NASH) and primary sclerosing cholangitis (PSC) .

Candidusin A CHNQD-0803	AMPK Apoptosis NF-κB TNF Receptor	Inflammation/Immunology
Candidusin A (CHNQD-0803) (Compound 4) is a AMPK activator with a K_D of 47.28 nM. Candidusin A can be isolated from marine fungus Aspergillus candidus. Candidusin A has cytotoxic activity and induces apoptosis in human prostate cancer cells (22Rv1, PC-3 and LNCaP cells). Candidusin A reduces adipogenesis genes expression and fat deposition, negatively regulates the NF-κB-TNFα inflammatory axis to suppress inflammation, and ameliorates liver injury and fibrosis. Candidusin A can be used for non-alcoholic steatohepatitis (NASH) research .

GLP-1R/GIPR agonist-1	GLP Receptor Insulin Receptor	Metabolic Disease
GLP-1R/GIPR AgonIST-1 is a double-receptor agonist for GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulin releasing peptide). GLP-1R/GIPR agonist-1 lowers blood sugar by mimicking the action of endogenous hormones GLP-1 and GIP, enhancing insulin secretion while inhibiting glucagon secretion. GLP-1R/GIPR agonist-1 can be used in the study of metabolic diseases such as diabetes, obesity, and non-alcoholic steatohepatitis (NASH) .

VX-166	Caspase	Inflammation/Immunology
VX-166, a pan caspase inhibitor, can be used for the research of Non- Alcoholic Fatty Liver Disease (NAFLD), nonalcoholic steatohepatitis (NASH), alcoholic steatohepatitis (ASH), and other diseases involving fibrosis, steatosis, or inflammation of the liver .

TE-8105	GLP Receptor	Metabolic Disease
TE-8105 is a GLP-1 receptor agonist that has demonstrated prolonged and potent efficacy in models of diabetes, obesity, and non-alcoholic steatohepatitis (NASH) .

HEC96719	FXR	Inflammation/Immunology
HEC96719 is a selective and orally active tricyclic farnesoid X receptor (FXR) agonist with EC₅₀ values of 1.37 and 1.55 nM by time-resolved fluorescence energy transfer (TR-FRET) and luciferase reporter assays, respectively. HEC96719 significantly improves non-alcoholic steatohepatitis (NASH) and liver fibrosis with favorable tissue distribution in liver and intestine. HEC96719 can be used for the research of non-alcoholic steatohepatitis .

ACC-IN-1	Acetyl-CoA Carboxylase	Inflammation/Immunology
ACC-IN-1 (Compound B1) is an allosteric inhibitor of acetyl-CoA carboxylase (ACC). ACC-IN-1 targets ACC to regulate lipid metabolism, which can improve liver steatosis, inflammation related to non-alcoholic steatohepatitis (NASH) .

MPO-IN-9	Reactive Oxygen Species (ROS)	Inflammation/Immunology
MPO-IN-9 is a selective inhibitor of myeloperoxidase (MPO), with an IC₅₀ value of 3.9 nM. MPO-IN-9 inhibits MPO-mediated ROS production and protects NO-dependent vascular function by blocking MPO's chlorination and peroxidation cycles. MPO-IN-9 can be used for the study of diseases such as chronic kidney disease (CKD), non-alcoholic steatohepatitis (NASH) .

SGP8	Dipeptidyl Peptidase	Inflammation/Immunology
SGP8 (IAVPGEVA) is an octapeptide produced by hydrolysis of soybean 11S globulin, which has the effects of regulating lipid metabolism, inflammation and fibrosis. SGP8 (IAVPGEVA) exhibits inhibitory activity against DPP4 and inhibits the JNK-c-Jun signaling pathway, and has the ability to inhibit non-alcoholic steatohepatitis (NASH) .

Cat. No.	Nombre del producto

HY-L199

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

4,703 compounds

Non-alcoholic fatty liver disease (NAFLD) is one of the most common liver diseases worldwide and is the primary liver manifestation of metabolic syndrome. The growth of NAFLD has coincided with the obesity epidemic. NAFLD is composed of excess lipid accumulation in the liver, causing steatotoxicity, and shows a wide range of histopathological abnormalities. NAFLD may progress from simple steatosis to Non-alcoholic steatohepatitis (NASH) with or without fibrosis (NASH), and eventually to cirrhosis and hepatocellular carcinoma. To date, very few drugs have been approved for marketing specifically for the treatment of NAFLD, so increased efforts to develop NAFLD drugs are necessary.

MCE designs a unique collection of 4,703 small molecules with definite or potential anti-NAFLD activity, which is an important tool for studying the pathological mechanism of NAFLD and developing drugs for NAFLD.

Cat. No.	Nombre del producto	Target	Research Area

HY-P3463

Beinaglutide 1 Publications Verification GLP-1 (human)	GCGR	Metabolic Disease Inflammation/Immunology
Beinaglutide is a human GLP-1 polypeptide that shares almost 100% homology with human GLP-1 (7–36). Beinaglutide displays does-dependent effects in glycemic control, inhibiting food intake and gastric empty and promoting weight loss. Beinaglutide has the potential for the research of overweight/obesity and nonalcoholic steatohepatitis (NASH) .

HY-145632

Pemvidutide ALT-801	GLP Receptor GCGR	Metabolic Disease
Pemvidutide (ALT-801) is a GLP-1R/GCGR dual agonist, shows striking reductions in body weight, liver fat and serum lipids. Pemvidutide can be used in non-alcoholic steatohepatitis (NASH) and obesity research .

HY-153476A

GIP/GLP-1 dual receptor agonist-1 sodium	GLP Receptor GCGR	Inflammation/Immunology
GIP/GLP-1 dual receptor agonist-1 sodium is a GIP/GLP-1 dual receptor agonist. GIP/GLP-1 dual receptor agonist-1 sodium is used in the research of metabolic disorders and fatty liver diseases, including non-alcoholic steatohepatitis (NASH) and non-alcoholic fatty liver disease (NAFLD) .

HY-153476

GIP/GLP-1 dual receptor agonist-1	GCGR GLP Receptor	Inflammation/Immunology
GIP/GLP-1 dual receptor agonist-1 is a GIP/GLP-1 dual receptor agonist. GIP/GLP-1 dual receptor agonist-1 is used in the research of metabolic disorders and fatty liver diseases, including non-alcoholic steatohepatitis (NASH) and non-alcoholic fatty liver disease (NAFLD) .

HY-145632A

Pemvidutide TFA ALT-801 TFA	GLP Receptor GCGR	Metabolic Disease
Pemvidutide (ALT-801) TFA is a GLP-1R/GCGR dual agonist, shows striking reductions in body weight, liver fat and serum lipids. Pemvidutide TFA can be used in non-alcoholic steatohepatitis (NASH) and obesity research .

HY-P10302

GLP-1R/GIPR agonist-1	GLP Receptor Insulin Receptor	Metabolic Disease
GLP-1R/GIPR AgonIST-1 is a double-receptor agonist for GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulin releasing peptide). GLP-1R/GIPR agonist-1 lowers blood sugar by mimicking the action of endogenous hormones GLP-1 and GIP, enhancing insulin secretion while inhibiting glucagon secretion. GLP-1R/GIPR agonist-1 can be used in the study of metabolic diseases such as diabetes, obesity, and non-alcoholic steatohepatitis (NASH) .

HY-P11042

TE-8105	GLP Receptor	Metabolic Disease
TE-8105 is a GLP-1 receptor agonist that has demonstrated prolonged and potent efficacy in models of diabetes, obesity, and non-alcoholic steatohepatitis (NASH) .

HY-P6177

SGP8	Dipeptidyl Peptidase	Inflammation/Immunology
SGP8 (IAVPGEVA) is an octapeptide produced by hydrolysis of soybean 11S globulin, which has the effects of regulating lipid metabolism, inflammation and fibrosis. SGP8 (IAVPGEVA) exhibits inhibitory activity against DPP4 and inhibits the JNK-c-Jun signaling pathway, and has the ability to inhibit non-alcoholic steatohepatitis (NASH) .

Cat. No.	Nombre del producto	Target	Research Area	Image

HY-P99428

Aldafermin NGM282	Inhibitory Antibodies	Metabolic Disease
Aldafermin (NGM282) is an analog of fibroblast growth factor 19. Aldafermin can be used for the research of nonalcoholic steatohepatitis (NASH) .

HY-P99697

Leronlimab PRO 140	CCR HIV	Infection Cancer
Leronlimab (PRO 140) is a humanized IgG4 anti-CCR5 monoclonal antibody. Leronlimab inhibits CCR5-mediated HIV-1 viral and lung metastasis in mouse tumor models. Leronlimab can be used for the research of HIV nonalcoholic steatohepatitis (NASH) and cancer .

HY-P99143

Anti-Mouse NK1.1 Antibody (PK136)	Neurokinin Receptor NF-κB STAT	Inflammation/Immunology
Anti-Mouse NK1.1 Antibody (PK136) is an anti-mouse NK1.1 IgG2a monoclonal antibody. Anti-Mouse NK1.1 Antibody (PK136) can deplete natural killer (NK) cells. Anti-Mouse NK1.1 Antibody (PK136) inhibits the JAK-STAT and NF-κB signaling pathways. Anti-Mouse NK1.1 Antibody (PK136) can be used for research on inflammation conditions such as non-alcoholic steatohepatitis (NASH) .

Cat. No.	Nombre del producto	Category	Target	Chemical Structure

HY-116374

Glycolithocholic acid 2 Publications Verification Lithocholylglycine	Human Gut Microbiota Metabolites Classification of Application Fields Endogenous metabolite Inflammation/Immunology Disease Research Fields Steroids Source Classification	Endogenous Metabolite
Glycolithocholic acid (Lithocholylglycine), an endogenous metabolite, is a glycine-conjugated secondary bile acid. Glycolithocholic acid can be used to diagnose ulcerative colitis (UC), non-alcoholic steatohepatitis (NASH) and primary sclerosing cholangitis (PSC) .

HY-W011121

2-Oleoylglycerol 1 Publications Verification 2-OG	Structural Classification Human Gut Microbiota Metabolites Classification of Application Fields Metabolic Disease Endogenous metabolite Disease Research Fields Lipid Source Classification	GPR119 NF-κB TGF-beta/Smad GLP Receptor
2-Oleoylglycerol (2-OG) is a lipid found in the diet. It is a GPR119 agonist, with an EC₅₀ value of 2.5 μM in activating hGPR119 in transiently transfected COS-7 cells. 2-Oleoylglycerol enhances the inflammatory response of macrophages and promotes fibrosis by activating the GPR119/TAK1/NF-κB/TGF-β1 signaling pathway. It also stimulates glucagon-like peptide 1 (GLP-1) secretion in vivo. 2-Oleoylglycerol is expected to be used in the research of non-alcoholic steatohepatitis (NASH) .

HY-116374R

Glycolithocholic acid (Standard) Lithocholylglycine (Standard)	Structural Classification Human Gut Microbiota Metabolites Endogenous metabolite Steroids Source Classification	Endogenous Metabolite Reference Standards
Glycolithocholic acid (Standard) is the analytical standard of Glycolithocholic acid. This product is intended for research and analytical applications. Glycolithocholic acid (Lithocholylglycine), an endogenous metabolite, is a glycine-conjugated secondary bile acid. Glycolithocholic acid can be used to diagnose ulcerative colitis (UC), non-alcoholic steatohepatitis (NASH) and primary sclerosing cholangitis (PSC) .

HY-N16066

Candidusin A CHNQD-0803	Monophenols Microorganisms Phenols Source Classification	AMPK Apoptosis NF-κB TNF Receptor
Candidusin A (CHNQD-0803) (Compound 4) is a AMPK activator with a K_D of 47.28 nM. Candidusin A can be isolated from marine fungus Aspergillus candidus. Candidusin A has cytotoxic activity and induces apoptosis in human prostate cancer cells (22Rv1, PC-3 and LNCaP cells). Candidusin A reduces adipogenesis genes expression and fat deposition, negatively regulates the NF-κB-TNFα inflammatory axis to suppress inflammation, and ameliorates liver injury and fibrosis. Candidusin A can be used for non-alcoholic steatohepatitis (NASH) research .

HY-N19083

Tecomella undulata extract	Structural Classification Extract	Bacterial
Tecomella undulata Extract, also known as Rohida extract, is a valuable botanical extract derived from the bark and leaves of the Tecomella undulata plant native to the Indian Thar Desert and is rich in bioactive compounds such as flavonoids, quinones, triterpenoids, and other phytochemicals that contribute to its diverse therapeutic properties. This extract is widely recognized for its hepatoprotective effects demonstrated through its ability to protect against liver damage induced by toxins such as paracetamol and carbon tetrachloride by normalizing elevated liver enzyme levels reducing oxidative stress and improving liver function. Additionally, it exhibits significant anti-inflammatory activity comparable to standard drugs like indomethacin and has been used to treat conditions like ascites and hepatosplenomegaly while also showing immunomodulatory effects by enhancing both humoral and cell-mediated immune responses and possessing antimicrobial properties that make it effective against various pathogens. Recent research suggests that Tecomella undulata may have potential in managing nonalcoholic steatohepatitis (NASH) by reducing body weight insulin resistance and improving liver function markers making it a versatile natural remedy with significant applications in hepatoprotection anti-inflammation and immune support.

Cat. No.	Nombre del producto	Chemical Structure

HY-116374S

Glycolithocholic acid-d4
Glycolithocholic acid-d₄ is the deuterium labeled Glycolithocholic acid. Glycolithocholic acid, an endogenous metabolite, is a glycine-conjugated secondary bile acid and can be used to diagnose ulcerative colitis (UC), non-alcoholic steatohepatitis (NASH) and primary sclerosing cholangitis (PSC) .

HY-W750488

Glycolithocholic acid-d5
Glycolithocholic acid-d₅ (Lithocholylglycine-d₅) is the deuterium labeled Glycolithocholic acid (HY-116374). Glycolithocholic acid (Lithocholylglycine), an endogenous metabolite, is a glycine-conjugated secondary bile acid. Glycolithocholic acid can be used to diagnose ulcerative colitis (UC), non-alcoholic steatohepatitis (NASH) and primary sclerosing cholangitis (PSC) .

HY-W701772

2-Oleoylglycerol-d5

2-Oleoylglycerol-d₅ (2-OG-d₅) is the deuterium labeled 2-Oleoylglycerol (HY-W011121). 2-Oleoylglycerol (2-OG) is a lipid found in the diet. It is a GPR119 agonist, with an EC₅₀ value of 2.5 μM in activating hGPR119 in transiently transfected COS-7 cells. 2-Oleoylglycerol enhances the inflammatory response of macrophages and promotes fibrosis by activating the GPR119/TAK1/NF-κB/TGF-β1 signaling pathway. It also stimulates glucagon-like peptide 1 (GLP-1) secretion in vivo. 2-Oleoylglycerol is expected to be used in the research of non-alcoholic steatohepatitis (NASH) .

HY-181896S

PPARγ agonist-23
PPARγ agonist-23 (Compound 9) is an orally active PPARγ agonist with an EC₅₀ of 0.32 μM. PPARγ agonist-23 improves hepatic triglyceride levels, reduces scores of steatosis and hepatocellular ballooning, and decreases the total activity score of non-alcoholic steatohepatitis (NASH). PPARγ agonist-23 can be used for the research of non-alcoholic steatohepatitis .

Consulta en línea

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Saludo			Country or Region *
Nombre del solicitante *			Nombre de la Organizaciòn *
Department *
Direcciòn del E-mail *			Nombre del producto *
Cat. No.			Requested quantity *
Número de teléfono *
Observaciones